U.S. Markets open in 4 hrs 6 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
284.42-9.66 (-3.28%)
At close: 4:00PM EDT

284.55 +0.13 (0.05%)
Pre-Market: 5:03AM EDT

People also watch
CELGREGNGILDAMGNALXN
Full screen
Previous Close294.08
Open293.07
Bid283.05 x 100
Ask287.65 x 100
Day's Range284.29 - 294.00
52 Week Range244.28 - 329.83
Volume1,590,602
Avg. Volume1,455,787
Market Cap60.14B
Beta0.53
PE Ratio (TTM)17.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com16 hours ago

    What's Up With Biogen?

    Shares of Biogen (BIIB) are falling today, which in itself isn’t hard to fathom given that the broader biotech sector is in decline. The iShares Nasdaq Biotechnology ETF (IBB) has dropped more than 1.1% ...

  • American City Business Journals2 days ago

    ​Biogen gains $1B in value after Goldman Sachs touts Alzheimer’s drug

    Biogen Inc. gained more than $1 billion in market value Wednesday morning after Goldman Sachs, one of the world’s largest investment banks, added the drug developer to its closely-watched Equity Conviction List. Goldman Sachs analysts Terence Flynn and Cameron Bradshaw issued a research note this morning announcing that Cambridge-based Biogen (BIIB) was added to the list, which is essentially a strong recommendation to general investors to buy stock in a certain company. In their research note, Flynn and Bradshaw pointed specifically to Biogen’s experimental drug to treat Alzheimer’s disease, called aducanumab, as a prime reason for the company’s inclusion on the list.

  • Goldman has a new favorite biotech because of potential Alzheimer's blockbuster
    CNBC2 days ago

    Goldman has a new favorite biotech because of potential Alzheimer's blockbuster

    Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.